Search

Displaying results 1811 - 1820 of 3020 in total
  1. Drug

    Dihydrostreptomycin

    go.drugbank.com/drugs/DB11512
    ApprovedVet approvedWithdrawn

    The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]

  2. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. DB00135 is a non-essential amino acid with a polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenou...

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  3. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    FDA approved on July 24, 2012.

  4. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Methotrexate (common treatment for RA patients) also has potential liver toxicity.} … Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis).

  5. Drug

    Zeatin

    go.drugbank.com/drugs/DB11337
    Investigational

    (Grant & Hackh's Chemical Dict, 5th ed)

    Synonyms: (E)-2-methyl-4-(1H-purin-6-ylamino)but-2-en-1-ol, (E)-zeatin
  6. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

    Mixtures: Clinimix E, Clinimix E
  7. Drug

    Ferric maltol

    go.drugbank.com/drugs/DB15598
    ApprovedInvestigational

    [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … [L10974] On December 22, 2025, the FDA expanded this indication to include pediatric patients aged 10 years and older. [L54873,L54878]

  8. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.

  9. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other...

  10. Drug

    Dilanubicel

    go.drugbank.com/drugs/DB18722
    Investigational

    Dilanubicel consists of ex vivo expanded hematopoietic stem and progenitor cells.